Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries
Rev Panam Salud Publica
; 46, 2022. Special Issue HEARTS
Article
in English
| PAHO-IRIS
| ID: phr-56272
Responsible library:
US1.1
ABSTRACT
[ABSTRACT]. Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in lowand middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average <US$ 5 per patient per year in the public sector. This health economic evidence will make a compelling case for government ownership and financial support for national scale hypertension control programs.
Full text:
Available
Collection:
Databases of international organizations
Health context:
SDG3 - Target 3.8 Achieve universal access to health
/
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
Health problem:
Multisectoral Coordination
/
Goal 9: Noncommunicable diseases and mental health
/
Target 3.8 Achieve universal access to health
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
Database:
PAHO-IRIS
Main subject:
Cardiovascular Diseases
/
Cost-Benefit Analysis
/
Health Services Accessibility
/
Hypertension
Type of study:
Health economic evaluation
Aspects:
Social determinants of health
Language:
English
Year:
2022
Document type:
Article